Printer Friendly

MARION MERRELL DOW LAUNCHES NICOTINE PATCH AS A NONPRESCRIPTION AID IN THE UNITED KINGDOM

 MARION MERRELL DOW LAUNCHES NICOTINE PATCH
 AS A NONPRESCRIPTION AID IN THE UNITED KINGDOM
 KANSAS CITY, Mo., Nov. 13 /PRNewswire/ -- Marion Merrell Dow Inc. (NYSE: MKC) today announced that its affiliate, Marion Merrell Dow Ltd., has introduced the Nicabate(TM) transdermal nicotine system in the United Kingdom as an aid to help people quit smoking. Starting this week, Nicabate is available in the United Kingdom either by physicians' prescription or directly from retail pharmacists.
 The Nicabate patch, which is marketed by Marion Merrell Dow as Nicoderm(R) in the United States and Canada, uses an advanced rate-controlling system to deliver a controlled dose of nicotine to the body over 24 hours. The company also markets Nicabate in New Zealand. As in North America, Marion Merrell Dow recommends a 10-week program to assist a "committed quitter," who stops smoking and then tapers off the nicotine level through three dosage strengths.
 The product was developed for Marion Merrell Dow and is manufactured by ALZA Corp. (NYSE: AZA) of Palo Alto, Calif., the pioneer in development of transdermal drug delivery technology.
 Marion Merrell Dow is a research-based global pharmaceutical organization dedicated to improving the longevity and quality of human life. The company is involved in the discovery, development, manufacture and sale of pharmaceutical products worldwide. In 1991, Marion Merrell Dow had sales of $2.85 billion and invested nearly $400 million in Research and Development.
 -0- 11/13/92
 /CONTACT: David M. Thompson or Richard M. Johnson of Marion Merrell Dow, 816-966-4000/
 (MKC AZA) CO: Marion Merrell Dow Inc.; ALZA Corp. ST: Missouri, California IN: MTC SU: PDT


BB -- DV003 -- 0608 11/13/92 10:28 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 13, 1992
Words:274
Previous Article:NATEC RESOURCES INC. ANNOUNCES THIRD QUARTER RESULTS
Next Article:SCIMED ANNOUNCES INTRODUCTION OF HIGH-PERFORMANCE, NON-COMPLIANT PTCA BALLOON CATHETER AND ITS FIRST CORONARY GUIDE WIRE
Topics:


Related Articles
MARION MERRELL DOW INTRODUCES FIRST NICOTINE PATCH FOR SMOKING CESSATION THERAPY
CARDIZEM(R) CD, ONCE-A-DAY HIGH BLOOD PRESSURE MEDICATION RELEASED FOR U.S MARKETING
ALZA, CYANAMID, ELAN AND MARION MERRELL CONCLUDE AGREEMENTS AND REACH AN OUT-OF-COURT SETTLEMENT
MARION MERRELL DOW REPORTS 25 PERCENT GAIN IN SECOND-QUARTER EARNINGS PER SHARE
MARION MERRELL DOW RECEIVES CLEARANCE TO MARKET ONCE-DAILY CARDIZEM CD FOR ANGINA
MARION MERRELL DOW ANNOUNCES RECORD SALES AND EARNINGS FOR 1992
MARION MERRELL DOW ANNOUNCES RECORD SALES AND EARNINGS FOR 1992
MARION MERRELL DOW INC. REPORTS SUBSTANTIALLY LOWER FIRST-QUARTER SALES, EARNINGS
MARION MERRELL DOW SIMPLIFIES GLOBAL BUSINESS STRUCTURE, NAMES LEADERS
COURT RULES IN FAVOR OF ALZA & MARION MERRELL DOW, DECLARES CIBA-GEIGY NICOTINE PATENT INVALID

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters